US Pharm. 2009;34(5):36-38.
The Generic Pharmaceutical Association (GPhA) said the availability of a workable pathway that provides timely patient access to safe, affordable, and life-saving biogeneric medicines would save consumers and the health care system billions of dollars. patients in need of life-saving biopharmaceutical treatments are struggling to afford their high costs. For patients facing serious conditions such as cancer and heart disease, safe and affordable biogenerics would allow them to improve their lives while reducing their health care costs," said Kathleen Jaeger, GPhA president and CEO.
